Welcome to Servatus
Servatus is an Australian biotechnology company operating with two complementary drug development platforms, offering primary and adjunct therapeutics for specific autoimmune, inflammatory and infectious conditions.
Servatus is an Australian biotechnology company operating with two complementary drug development platforms, offering primary and adjunct therapeutics for specific autoimmune, inflammatory and infectious conditions.
Servatus has isolated and characterised unique microbial species and has conducted thorough preclinical research to formulate new medicines targeting autoimmune, inflammatory, and infectious conditions.
Ongoing human clinical trials aim to validate the clinical efficacy of these drugs, with the ultimate goal of advancing safe and effective treatments.
A pivotal endeavour involves creating pharmaceutical-grade live biotherapeutic agents derived primarily from bacterial microorganisms.
As existing medications approach their limitations in delivering long-term efficacy and safety, exploring novel mechanisms of action offers the most promising avenue for advancing medical treatments in the future.
Servatus' engineered protein research is focussed on enhancing specific therapeutic characteristics of select proteins to develop safe and effective treatments for immune-mediated inflammatory diseases. By targeting crucial protein characteristics, Servatus aims to enhance their clinical efficacy and supplement current drug therapies.
Servatus has pioneered the engineering of a modified protein selected for its inherent immune-modulating capabilities, with expectations of bolstering clinical efficacy and optimising commercial delivery.
Learn more about the latest news in Australian biopharmaceutical research and our work in progressing the science for better autoimmune drugs.